Invivyd (IVVD) Cash from Financing Activities (2021 - 2025)
Invivyd (IVVD) posted Cash from Financing Activities of $157.2 million for Q4 2025, up 169.54% on a QoQ basis from $58.3 million in Q3 2025, and up 204025.97% year-over-year from N/an in Q4 2024.
Invivyd (IVVD) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Invivyd's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $157.2 million for Q4 2025.
- Quarterly Cash from Financing Activities rose 204025.97% year-over-year to $157.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $215.6 million (up 448.24% YoY) and the FY2025 annual result came in at $215.6 million, up 448.24% from the prior year.
- Cash from Financing Activities was $157.2 million for Q4 2025 at Invivyd, up from $58.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $334.8 million in Q2 2021 and bottomed at -$749000.0 in Q4 2021.
- A 5-year average of $48.4 million and a median of $141000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 99.98% — and 2025, when it jumped 204025.97%.
- Invivyd's Cash from Financing Activities stood at -$749000.0 in 2021, then jumped by 118.83% to $141000.0 in 2022, then changed by 0.0% to $141000.0 in 2023, then slumped by 45.39% to $77000.0 in 2024, then soared by 204025.97% to $157.2 million in 2025.
- Business Quant data shows IVVD's Cash from Financing Activities at $157.2 million in Q4 2025, $58.3 million in Q3 2025, and $131000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Invivyd | 104.64 Mn | -122.05 Mn | 16.07 Mn | 157.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 157.18 Mn |
| Dec 31, 2025 | 157.18 Mn |
| Sep 30, 2025 | 58.31 Mn |
| Sep 30, 2025 | 58.31 Mn |
| Jun 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Mar 31, 2024 | 39.10 Mn |
| Mar 31, 2024 | 39.10 Mn |
| Dec 31, 2023 | 141,000.00 |
| Dec 31, 2023 | 141,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Sep 30, 2023 | 92,000.00 |